BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 20634336)

  • 1. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
    Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
    Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation and identification of the human N+-glucuronide metabolite of cediranib.
    Lenz EM; Spear M; Drake C; Pollard CR; Ward M; Schulz-Utermoehl T; Harrison M
    J Pharm Biomed Anal; 2010 Nov; 53(3):526-36. PubMed ID: 20409669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.
    Sharer JE; Shipley LA; Vandenbranden MR; Binkley SN; Wrighton SA
    Drug Metab Dispos; 1995 Nov; 23(11):1231-41. PubMed ID: 8591724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
    Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
    Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin.
    Eberhart DC; Gemzik B; Halvorson MR; Parkinson A
    Mol Pharmacol; 1991 Nov; 40(5):859-67. PubMed ID: 1944247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
    Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
    Rodrigues AD; Kukulka MJ; Ferrero JL; Cashman JR
    Drug Metab Dispos; 1995 Oct; 23(10):1143-52. PubMed ID: 8654204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist.
    Karanam BV; Welch CJ; Reddy VG; Chilenski J; Biba M; Vincent S
    Drug Metab Dispos; 2004 Oct; 32(10):1061-8. PubMed ID: 15229170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.
    Uchiyama M; Koda H; Fischer T; Mueller J; Yamamura N; Oguchi M; Iwabuchi H; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 Jul; 39(7):1311-9. PubMed ID: 21511943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
    Kazmi F; Barbara JE; Yerino P; Parkinson A
    Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
    Albrecht W; Unger A; Nussler AK; Laufer S
    Drug Metab Dispos; 2008 May; 36(5):894-903. PubMed ID: 18268076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases.
    Karanam BV; Hop CE; Liu DQ; Wallace M; Dean D; Satoh H; Komuro M; Awano K; Vincent SH
    Drug Metab Dispos; 2004 Sep; 32(9):1015-22. PubMed ID: 15319344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
    Kaji H; Kume T
    Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.
    Li C; Kuchimanchi M; Hickman D; Poppe L; Hayashi M; Zhou Y; Subramanian R; Kumar G; Surapaneni S
    Drug Metab Dispos; 2009 Jul; 37(7):1378-94. PubMed ID: 19372226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
    Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices.
    Steensma A; Beamand JA; Walters DG; Price RJ; Lake BG
    Xenobiotica; 1994 Sep; 24(9):893-907. PubMed ID: 7810171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative detoxication of carcinogenic 2-nitroanisole by human, rat and rabbit cytochrome P450.
    Dracínska H; Miksanová M; Svobodová M; Smrcek S; Frei E; Schmeiser HH; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():9-13. PubMed ID: 17159769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential metabolism of sesamin by cytochrome P450 and UDP-glucuronosyltransferase in human liver.
    Yasuda K; Ikushiro S; Kamakura M; Munetsuna E; Ohta M; Sakaki T
    Drug Metab Dispos; 2011 Sep; 39(9):1538-45. PubMed ID: 21622626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.